Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells

Experimental Cell Research

Volumn 318, Issue 10, 2012, Pages 1112-1124

  Jamnani, Fatemeh Rahimi ^a   Rahbarizadeh, Fatemeh ^b   Shokrgozar, Mohammad A ^a   Ahmadvand, Davoud ^c   Mahboudi, Fereidoun ^a   Sharifzadeh, Zahra ^a  

^a PASTEUR INSTITUTE OF IRAN   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Breast cancer; HER2; Immunotherapy; Nanobodies; Oligoclonal

Indexed keywords

ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; OLIGOCLONAL NANOBODY; TRASTUZUMAB; TUMOR MARKER; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG PROTEIN BINDING; EMBRYO; EPITOPE MAPPING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 84860374584     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.03.004     Document Type: Article

References (40)

1. Bosch A., Eroles P., Zaragoza R., Vina J.R., Lluch A. Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat. Rev. 2010, 36:206-215.
2. Moulder S., Hortobagyi G.N. Advances in the treatment of breast cancer. Clin. Pharmacol. Ther. 2008, 83:26-36.
3. Gianni L., Eiermann W., Semiglazov V., Manikhas A., Lluch A., Tjulandin S., Zambetti M., Vazquez F., Byakhow M., Lichinitser M., Climent M.A., Ciruelos E., Ojeda B., Mansutti M., Bozhok A., Baronio R., Feyereislova A., Barton C., Valagussa P., Baselga J. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 2010, 375:377-384.
4. Emde A., Pradeep C.R., Ferraro D.A., Ben-Chetrit N., Sela M., Ribba B., Kam Z., Yarden Y. Combining epitope-distinct antibodies to HER2: cooperative inhibitory effects on invasive growth. Oncogene 2011, 30:1631-1642.
5. Helguera G., Rodriguez J.A., Penichet M.L. Cytokines fused to antibodies and their combinations as therapeutic agents against different peritoneal HER2/neu expressing tumors. Mol. Cancer Ther. 2006, 5:1029-1040.
6. A. Emde, W.J. Kostler, Y. Yarden, Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer, Crit. Rev. Oncol. Hematol. (in press).
7. Kolkman J.A., Law D.A. Nanobodies-from llamas to therapeutic proteins. Drug Discov. Today: Technol. 2010, 7:139-146.
8. Saerens D., Ghassabeh G.H., Muyldermans S. Single-domain antibodies as building blocks for novel therapeutics. Curr. Opin. Pharmacol. 2008, 8:600-608.
9. Harmsen M.M., De Haard H.J. Properties, production, and applications of camelid single-domain antibody fragments. Appl. Microbiol. Biotechnol. 2007, 77:13-22.
10. Roovers R.C., Laeremans T., Huang L., De Taeye S., Verkleij A.J., Revets H., de Haard H.J., van Bergen en Henegouwen P.M. Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies. Cancer Immunol. Immunother. 2007, 56:303-317.
11. Sharon J., Liebman M.A., Williams B.R. Recombinant polyclonal antibodies for cancer therapy. J. Cell. Biochem. 2005, 96:305-313.
12. Ben-Kasus T., Schechter B., Lavi S., Yarden Y., Sela M. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:3294-3299.
13. Baselga J., Gelmon K.A., Verma S., Wardley A., Conte P., Miles D., Bianchi G., Cortes J., McNally V.A., Ross G.A., Fumoleau P., Gianni L. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J. Clin. Oncol. 2010, 28:1138-1144.
14. Ahmadvand D., Rasaee M.J., Rahbarizadeh F., Kontermann R.E., Sheikholislami F. Cell selection and characterization of a novel human endothelial cell specific nanobody. Mol. Immunol. 2009, 46:1814-1823.
15. Beatty J.D., Beatty B.G., Vlahos W.G. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J. Immunol. Methods 1987, 100:173-179.
16. Deckers N., Saerens D., Kanobana K., Conrath K., Victor B., Wernery U., Vercruysse J., Muyldermans S., Dorny P. Nanobodies, a promising tool for species-specific diagnosis of Taenia solium cysticercosis. Int. J. Parasitol. 2009, 39:625-633.
17. Beckman R.A., Weiner L.M., Davis H.M. Antibody constructs in cancer therapy: protein engineering strategies to improve exposure in solid tumors. Cancer 2007, 109:170-179.
18. Elbakri A., Nelson P.N., Abu Odeh R.O. The state of antibody therapy. Hum. Immunol. 2010, 71:1243-1250.
19. Jamieson D., Cresti N., Verrill M.W., Boddy A.V. Development and validation of cell-based ELISA for the quantification of trastuzumab in human plasma. J. Immunol. Methods 2009, 345:106-111.
20. Scheuer W., Friess T., Burtscher H., Bossenmaier B., Endl J., Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009, 69:9330-9336.
21. Zagozdzon R., Gallagher W.M., Crown J. Truncated HER2: implications for HER2-targeted therapeutics. Drug Discov. Today 2011, 16:810-816.
22. Muyldermans S. Single domain camel antibodies: current status. J. Biotechnol. 2001, 74:277-302.
23. Thys B., Schotte L., Muyldermans S., Wernery U., Hassanzadeh-Ghassabeh G., Rombaut B. In vitro antiviral activity of single domain antibody fragments against poliovirus. Antiviral Res. 2010, 87:257-264.
24. Rahbarizadeh F., Ahmadvand D., Sharifzadeh Z. Nanobody; an old concept and new vehicle for immunotargeting. Immunol. Invest. 2011, 40:299-338.
25. Rahbarizadeh F., Rasaee M.J., Forouzandeh Moghadam M., Allameh A.A., Sadroddiny E. Production of novel recombinant single-domain antibodies against tandem repeat region of MUC1 mucin. Hybrid. Hybridomics 2004, 23:151-159.
26. Bakhtiari S.H., Rahbarizadeh F., Hasannia S., Ahmadvand D., Iri-Sofla F.J., Rasaee M.J. Anti-MUC1 nanobody can redirect T-body cytotoxic effector function. Hybridoma (Larchmt) 2009, 28:85-92.
27. Sadeqzadeh E., Rahbarizadeh F., Ahmadvand D., Rasaee M.J., Parhamifar L., Moghimi S.M. Combined MUC1-specific nanobody-tagged PEG-polyethylenimine polyplex targeting and transcriptional targeting of tBid transgene for directed killing of MUC1 over-expressing tumour cells. J. Control. Release 2011, 156:85-91.
28. Vaneycken I., Devoogdt N., Van Gassen N., Vincke C., Xavier C., Wernery U., Muyldermans S., Lahoutte T., Caveliers V. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J. 2011, 25:2433-2446.
29. Kawa S., Matsushita H., Ohbayashi H., Semba K., Yamamoto T. A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth. Biochem. Biophys. Res. Commun. 2009, 384:329-333.
30. Adams G.P., Schier R. Developing anti-HER2/neu single-chain Fv fragments from phage display libraries. Methods Mol. Med. 2001, 39:729-747.
31. Ryckaert S., Pardon E., Steyaert J., Callewaert N. Isolation of antigen-binding camelid heavy chain antibody fragments (nanobodies) from an immune library displayed on the surface of Pichia pastoris. J. Biotechnol. 2010, 145:93-98.
32. Marks C., Marks J.D. Phage libraries-a new route to clinically useful antibodies. N. Engl. J. Med. 1996, 335:730-733.
33. Williams B., Atkins A., Zhang H., Lu D., Jimenez X., Li H., Wang M.N., Ludwig D., Balderes P., Witte L., Li Y., Zhu Z. Cell-based selection of internalizing fully human antagonistic antibodies directed against FLT3 for suppression of leukemia cell growth. Leukemia 2005, 19:1432-1438.
34. Schreiber G., Keating A.E. Protein binding specificity versus promiscuity. Curr. Opin. Struct. Biol. 2011, 21:50-61.
35. Tse C., Gauchez A.S., Jacot W., Lamy P.J. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat. Rev. 2012, 38:133-142.
36. Ghedini G.C., Ciravolo V., Tortoreto M., Giuffre S., Bianchi F., Campiglio M., Mortarino M., Figini M., Coliva A., Carcangiu M.L., Zambetti M., Piazza T., Ferrini S., Menard S., Tagliabue E., Pupa S.M. Shed HER2 extracellular domain in HER2-mediated tumor growth and in trastuzumab susceptibility. J. Cell. Physiol. 2010, 225:256-265.
37. Yip Y.L., Smith G., Koch J., Dubel S., Ward R.L. Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. J. Immunol. 2001, 166:5271-5278.
38. Lewis Phillips G.D., McMurtrey A.E., Schroeder K., Fendly B.M. Diverse activities of anti-HER2 monoclonal antibodies: from growth inhibition to induction of apoptosis. Proc. Am. Assoc. Cancer Res 1998, 39.
39. Haurum J.S. Recombinant polyclonal antibodies: the next generation of antibody therapeutics?. Drug Discov. Today 2006, 11:655-660.
40. Spangler J.B., Neil J.R., Abramovitch S., Yarden Y., White F.M., Lauffenburger D.A., Wittrup K.D. Combination antibody treatment down-regulates epidermal growth factor receptor by inhibiting endosomal recycling. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:13252-13257.